151 related articles for article (PubMed ID: 16033997)
1. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
2. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells.
Gho YS; Chae CB
Mol Cells; 1999 Feb; 9(1):31-6. PubMed ID: 10102568
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract][Full Text] [Related]
5. In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.
Eluu SC; Obayemi JD; Salifu AA; Yiporo D; Oko AO; Aina T; Oparah JC; Ezeala CC; Etinosa PO; Ugwu CM; Esimone CO; Soboyejo WO
Sci Rep; 2024 Jan; 14(1):31. PubMed ID: 38167999
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
[TBL] [Abstract][Full Text] [Related]
7. LHRH-Targeted Drug Delivery Systems for Cancer Therapy.
Li X; Taratula O; Taratula O; Schumann C; Minko T
Mini Rev Med Chem; 2017; 17(3):258-267. PubMed ID: 27739358
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.
Ndinguri M; Middleton L; Unrine J; Lui S; Rollins J; Nienaber E; Spease C; Williams A; Cormier L
PLoS One; 2023; 18(10):e0287151. PubMed ID: 37816015
[TBL] [Abstract][Full Text] [Related]
9. Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues.
Ezenwafor TC; Uzonwanne VO; Madukwe JUA; Amin SM; Anye VC; Obayemi JD; Odusanya OS; Soboyejo WO
J Mech Behav Biomed Mater; 2022 Dec; 136():105461. PubMed ID: 36195050
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance and targeted therapies in ovarian and endometrial cancers.
Brasseur K; Gévry N; Asselin E
Oncotarget; 2017 Jan; 8(3):4008-4042. PubMed ID: 28008141
[TBL] [Abstract][Full Text] [Related]
11. Role of gonadotropin-releasing hormone 2 and its receptor in human reproductive cancers.
Desaulniers AT; White BR
Front Endocrinol (Lausanne); 2023; 14():1341162. PubMed ID: 38260130
[TBL] [Abstract][Full Text] [Related]
12. Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers.
Sananes A; Cohen I; Allon I; Ben-David O; Abu Shareb R; Yegodayev KM; Stepensky D; Elkabets M; Papo N
Mol Oncol; 2023 Nov; 17(11):2337-2355. PubMed ID: 37609678
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer.
Vishwasrao HM; Master AM; Seo YG; Liu XM; Pothayee N; Zhou Z; Yuan D; Boska MD; Bronich TK; Davis RM; Riffle JS; Sokolsky-Papkov M; Kabanov AV
Chem Mater; 2016 May; 28(9):3024-3040. PubMed ID: 37405207
[TBL] [Abstract][Full Text] [Related]
14. Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function.
Loibl S; Fersis N; Harbeck N
Breast Care (Basel); 2011 Dec; 6(6):467-470. PubMed ID: 22419902
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
Emons G; Gorchev G; Harter P; Wimberger P; Stähle A; Hanker L; Hilpert F; Beckmann MW; Dall P; Gründker C; Sindermann H; Sehouli J
Int J Gynecol Cancer; 2014 Feb; 24(2):260-5. PubMed ID: 24418927
[TBL] [Abstract][Full Text] [Related]
16. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
Engel JB; Tinneberg HR; Rick FG; Berkes E; Schally AV
Curr Drug Targets; 2016; 17(5):488-94. PubMed ID: 26951061
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
19. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
